← Evidence map

ArticleTargeted oncology2026

Comment on: "First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies".

Reza Izadpanah et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Comment on: "First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies". | OpenQuestion